The European Investment Bank has signed a €25 million venture debt facility with Salvia BioElectronics, the Dutch medtech. The bank's public project register records the signature on 29 July 2026.
The register says the loan will support research, development and clinical evaluation of an implantable neurostimulation device for chronic migraine and cluster headache. It describes the financing as direct, equity-type support under the EIB's venture debt instrument. The bank put the wider project cost at about €59 million and approved the operation on 24 June. The facility is backed by InvestEU and sits under the EIB Group's TechEU programme. The borrower on the project sheet is Salvia BioElectronics BV. The EIB said the facility will extend Salvia's cash runway and help attract further private capital, and that InvestEU backing lets it provide long-term venture debt to a company that currently lacks access to commercial debt.
Salvia, founded in 2017 and based in Eindhoven, is a clinical-stage medtech developing implantable neurostimulation for chronic migraine and cluster headache.
On 27 May 2025 Salvia closed a $60 million (€53 million) Series B led by Innovation Industries, a European deeptech venture capital firm. Invest-NL and the EIC Fund participated, as did existing investors Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, BOM and Thuja Capital. The company said the money would fund completion of clinical development and commercial launch preparations in the United States, Europe and Australia. It also said the proceeds would support work towards FDA market authorisation in the United States and regulatory approvals in Europe and Australia.
The EIB says venture debt is typically between €10 million and €50 million and is available to European SMEs and mid-caps that have already raised equity from professional investors. It describes the product as complementing venture capital, with a more limited effect on ownership than a new share issue. The bank typically offers this form of long-term financing to companies developing technologies in life sciences, deep tech and cleantech.
The Salvia facility is supported by InvestEU, the EU programme that uses a €26.2 billion budget guarantee to crowd public and private capital into policy-priority projects. The EIB Group is the main implementing partner. The bank said the operation is in line with InvestEU's research, development and innovation objective.